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Background: Although a number of studies have reported acquired drug resistance due to administration of
epidermal growth factor receptor antibody inhibitors, the underlying causes of this phenomenon remain unclear.
Case presentation: Here we report a case of a 75-year-old man with liver metastasis at 3 years after a successful
transverse colectomy to treat KRAS wild-type colorectal cancer. While initial administration of epidermal growth
factor receptor inhibitors proved effective, continued use of the same treatment resulted in new peritoneal seeding.
An acquired KRAS mutation was found in a resected tissue specimen from one such area. This mutation, possibly
caused by administration of epidermal growth factor receptor inhibitors, appears to have conferred drug resistance.
Conclusion: The present findings suggest that administration of epidermal growth factor receptor inhibitors results
in an acquired KRAS mutation that confers drug resistance.
Keywords: KRAS, Acquired resistance, CetuximabBackground
A better understanding of the mechanisms underlying
changes in KRAS in response to epidermal growth
factor receptor (EGFR) inhibitors might contribute to
improvement in the treatment of colorectal cancer (CRC).
Here we report a case of an acquired KRAS mutation that
appears to have conferred drug resistance following
administration of cetuximab and discuss it in light of
the recent literature.
Case presentation
The patient was a 75-year-old man with a history of
hypertension, cerebrovascular disease, and adjustment
disorder, but no known allergies. The patient’s father
also had a history of colon cancer.
In December 2004, the patient underwent a transverse
colectomy for transverse colon cancer (T3 N1 M0 stage
IIIa) at another hospital. Due to adjustment disorder, the* Correspondence: satoshi.matsusaka@jfcr.or.jp
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reproduction in any medium, provided the orpatient was closely monitored, but no adjuvant chemo-
therapy administered.
In March 2006, a colonoscopy revealed that the cancer
had anastemotic recurrence, and in April 2006 the patient
underwent a subtotal colectomy and anastomosis of the
sigmoid colon and ileum.
In April 2007, the patient’s tumor markers were elevated
and positron emission tomography-computed tomography
(PET-CT) revealed metastasis to the liver and para-aortic
lymph nodes. Chemotherapy with 5-fluorouracil/leu-
covorin/ oxaliplatin (FOLFOX4) was started as first-line
treatment in May 2007. After 15 courses of treatment,
the patient exhibited signs of progressive disease. Bevaci-
zumab could not be administered, however, as the patient
also had cerebrovascular disease.
In February 2008, chemotherapy with 5-fluorouracil/ leu-
covorin/irinotecan (FOLFIRI) was started as second-line
treatment. After 16 courses of treatment, imaging revealed
an increase in liver metastasis, and the patient was referred
to our hospital.
At the time of admission, the patient measured 186.5 cm
in height, weighed 80.1 kg, had a Body Mass Index (BMI)Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Response of liver metastases to CPT-11-cetuximab.
After 13 courses of chemotherapy with irinotecan and cetuximab
(CPT-11 + C-mab), blood levels of CEA and CA19-9 dropped to
14.3 ng/mL and 16.8 U/mL, respectively, and liver metastases
showed reduction, indicating partial response.
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sounds and breathing were noted, without abdominal
abnormalities being observed, there was no leg edema,
and the patient had grade1 peripheral neuropathy. Blood
tests showed a normal blood count, and blood levels of
carcinoembryonic antigen (CEA) and carbohydrate antigen
(CA)19-9 at 88.8 ng/mL and 312.2 U/mL, respectively.
Chest and abdominal X-rays, as well as an electrocar-
diogram, also revealed no abnormalities. An abdominal
CT showed shadows on his liver at S4 and S8 (Figure 1).
A PET-CT scan (1/29) showed liver metastases at S8,
S4 and S3. The resected primary tumor tested positive
for EGFR and showed the presence of wild-type KRAS.
EGFR was analyzed by immunohistochemistry.
KRAS genotyping using tumor samples was analyzed
by Luminex® assay.
The analytical sensitivity of the Luminex® assay is 0.4%
(GENOSEARCH HS KRAS).
After admission, chemotherapy with irinotecan and
cetuximab (CPT-11 + C-mab) was started as third-line
treatment in January 2009. After 13 courses of treatment,
blood CEA and CA19-9 levels dropped to 14.3 ng/mL
and 16.8 U/mL, respectively, and liver metastases showed
a reduction (Figure 2), indicating a partial response. A left
hepatectomy was performed in September 2009, and
tumor markers dropped to normal levels. The resected
tumor specimen showed the presence of wild-type KRAS.
In October 2009, postoperative chemotherapy was com-
menced with CPT-11 + C-mab. Six courses (courses
14–19) of treatment were completed, after which the
patient only came in for follow-up without continuing
chemotherapy.
In July 2010, the patient exhibited peritoneal dissemin-
ation and lung metastasis (S2,S4,S5,S8), and treatment
with CPT-11 + C-mab was recommenced. After 18 courses
of treatment (courses 20–37), no change was observedFigure 1 Computed tomography of liver metastasis. Abdominal
CT showing shadows on liver at S4 and S8.in lung metastases, and no new areas of metastasis
were detected, indicating stable disease (SD).
In August 2011, the patient underwent lung metastasis
resection. In October 2011, new areas of lung metastasis
were found, while the primary tumor remained unchanged
(SD). Treatment with CPT-11 + C-mab was started again
(courses 38–48). Courses 39–41 and 45–48 consisted of
only cetuximab. The lung metastases remained unchanged
(SD) after 11 courses of treatment.
In May 2012, emergency gastric bypass surgery was
performed for an obstruction in the ileum due to seeding
in the patient’s duodenum (Figure 3). A KRAS mutation
was detected in the resected seeding tissue.
At present, only palliative treatment is being adminis-
tered as the patient has completed standard treatment.Figure 3 Obstruction in ileum due to seeding in duodenum.
In May 2012, patient had obstruction in ileum due to seeding in
duodenum. Emergency gastric bypass surgery was performed. KRAS
mutation was detected in resected seeding tissue.
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and 2009 showed the presence of wild-type KRAS, and
the administration of cetuximab for 2 years and 4 months
proved effective, the resected seeding tissue from his
intestinal obstruction was found to have a KRAS mutation.
Hence, it can be possibly concluded that administration of
EGFR inhibitors resulted in an acquired KRAS mutation
that conferred drug resistance.
Conclusions
In 1988, Vogelstein et al. proposed a multi-stage theory
of carcinogenesis known as the adenoma-carcinoma
sequence, in which colorectal cancer arises due to mu-
tations that activate multiple oncogenes and inactivate
tumor suppressor genes, which then accumulate on
the epithelium of a normal colon, forming adenomas.
KRAS mutations were proposed to be driver mutations
in colorectal carcinogenesis [1]. Earlier studies have
noted similar KRAS mutations in both the primary
tumor and metastases in more than 90% of patients
with CRC or lung cancer [2,3]. Moreover, in addition
to these two studies, another report also noted a small
number of cases of KRAS mutations in metastases arising
from wild-type KRAS primary tumors [4]. Colorectal
tumors with wild-type KRAS are often sensitive to EGFR
blockade [5]. The mechanism underlying an acquired
resistance to EGFR inhibitors, however, remains largely
unknown. The previously reported lower concordance
levels of KRAS between the primary tumor and metastases
are likely due to bias arising from false-negative results
in underpowered studies and the correct evaluation of the
amount of tumor tissue in the sample, or the sensitivity
of the testing method used [6]. Previously published
data showed that a considerable fraction of colorectal
lymph node metastases do not resemble the primary
tumor in terms of KRAS mutation status [4]. Hetero-
geneity in lymph node metastases could explain this
discordance in a small number of cases, but its main
mechanism is unknown. Misale et al. also reported that
use of anti-EGFR drugs for metastatic CRC contributed
to acquisition of a KRAS mutation [7]. There are two
possible explanations for the discordant results for
KRAS: heterogeneity of KRAS status within the primary
tumor [8-10], or clonal selection during the process of
metastasis [6]. Another clinical study identified wild-
type KRAS in 10 patients with acquired resistance to
anti-EGFR therapy. Meanwhile, a KRAS G13D mutation
was identified in 4 further cases, and the simultaneous
presence of G12D and G13D mutations in one. In 6
patients for whom sufficient pre-treatment tumor samples
were available for high-coverage 454 sequence analyses
or beads, emulsion, amplification and magnetics, KRAS
mutations were found to be absent. Tumors from a further
8 patients treated with cytotoxic chemotherapy but notpreviously exposed to anti-EGFR therapies were also
analyzed by 454 deep sequencing. In all 8 cases, the
analyses identified no evidence of a KRAS mutation.
These results indicate an association between treatment
with anti-EGFR antibodies, not cytotoxic chemotherapy,
and acquisition of KRAS mutations [7]. The mechanism
of resistance to anti-EGFR therapy has recently been
clarified. Montagut et al. reported an acquired EGFR
ectodomain mutation (S492R) that prevented cetuximab
binding, thus conferring resistance to this drug. The
cells with this mutation, however, retained binding to
panitumumab, which inhibited their growth. In that
study, 2 of 10 patients acquired this mutation after
cetuximab treatment. One patient with cetuximab re-
sistance and harboring the S492R mutation responded
to treatment with panitumumab. This indicates that
panitumumab may be effective in patients with the
S492R mutation after failure of cetuximab. A re-biopsy
would be needed before commencing treatment with a
molecularly targeted drug, however [10,11]. In further
study, we aim to analyze KRAS status by using circulating
tumor cells, which play a core role in liquid biopsy.
Resistant cells remained sensitive to combinatorial
inhibition of EGFR and mitogen-activated protein-kinase
(MEK), and mutated KRAS alleles were detected in
the blood of cetuximab-treated patients as early as
10 months before radiographic documentation of disease
progression [7].
In summary, there is a growing body of evidence to
suggest that EGFR inhibitor-induced KRAS mutations
that associates with tumor recurrence. The results of
the present study suggest that such mutations could be
identified non-invasively months before disease progres-
sion became evident radiographically, and that early
initiation of a MEK inhibitor would be a rational strategy
for delaying or reversing drug resistance. If such strategies
were employed, this might allow ineffective drugs to be
terminated earlier and more effective treatment strategies
pursued.Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.Abbreviations
CT: Computed tomography; PET-CT: Positron emission tomography-computed-
tomograpy; Bev: BGevacizumab; BMI: Body mass index; PS: Performance status;
CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen; BEAMing: Beads,
emulsion, amplification and magnetics; CTCs: Circulating tumor cells.Competing interests
The authors declare that they have no competing interests.
Osumi et al. BMC Research Notes 2013, 6:508 Page 4 of 4
http://www.biomedcentral.com/1756-0500/6/508Authors’ contributions
The original manuscript was written by HO. HO and MS and ES and MS and NM
performed chemotherapy for mCRC. AS and MU and TY performed a left
hepatectomy, MM performed a lung resection. All authors contributed to drafting
and editing the manuscript. All authors read and approved the final manuscript.
Author details
1Department of Gastroenterology, Cancer Institute Hospital of Japanese
Foundation for Cancer Research, 3-8-31 Ariake, 135-8550, Koto-ku,
Tokyo, Japan. 2Surgery, Koto-ku, Japan. 3Thoracic Center, Koto-ku, Japan.
Received: 21 June 2013 Accepted: 28 November 2013
Published: 5 December 2013
References
1. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M,
Nakamura Y, White R, Smits AM, Bos JL: Genetic alterations during
colorectal-tumor development. N Engl J Med 1998, 319:525–532.
2. Han CB, Li F, Ma JT, Zou HW: Concordant KRAS mutations in primary and
metastatic colorectal cancer tissue specimens: a meta-analysis and
systematic review. Cancer Invest 2012, 30(10):741–747.
3. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K,
Iinuma H, Shibuya H, Eshima K: Heterogeneity of KRAS status may explain
the subset of discordant KRAS status between primary and metastatic
colorectal cancer. Dis Colon Rectum 2011, 54(9):1170–1178.
4. Knijn N, Mekenkamp LJ, Klomp M, Vink-Börger ME, Tol J, Teerenstra S, Meijer JW,
Tebar M, Riemersma S, Van Krieken JH, Punt CJ, Nagtegaal ID: KRAS mutation
analysis: a comparison between primary tumours and matched liver metas-
tases in 305 colorectal cancer patients. Br J Cancer 2011, 104(6):1020–1026.
5. Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med
2008, 358:1160–1174.
6. Bouchahda M, Karaboué A, Saffroy R, Innominato P, Gorden L, Guettier C,
Adam R, Lévi F: Acquired KRAS mutations during progression of
colorectal cancer metastases: possible implications for therapy and
prognosis. Cancer Chemotherapy Pharmacol 2010, 66(3):605–609.
7. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E,
Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT,
Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E,
Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A:
Emergence of KRAS mutation and acquired resistance to anti-EGFR therapy
in colorectal cancer. Nature 2012, 486(7404):532–536.
8. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I,
Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B: The molecular
evolution of acquired resistance to targeted EGFR blockade in colorectal
cancers. Nature 2012, 486(7404):537–540.
9. Li Z, Jin K, Lan H, Teng L: Heterogeneity in primary colorectal cancer and
its corresponding metastases: a potential reason of EGFR-targeted therapy
failure? Hepatogastroenterology 2011, 58(106):411–416.
10. Bardelli A, Jänne PA: The road to resistance : EGFR mutation and
cetuximab. Nature medicine 2012, 18:199–200.
11. Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M,
Gallen M, Marsters S, Tsai SP, Minoche A, Seshagiri S, Serrano S, Himmelbauer H,
Bellmunt J, Rovira A, Settleman J, Bosch F, Albanell J: Identification of a
mutation in the extracellular domain of the epidermal growth facter
receptor conferring cetuximab resistance in colorectal cancer.
Nature medicine 2012, 18(2):221–223.
doi:10.1186/1756-0500-6-508
Cite this article as: Osumi et al.: Acquired drug resistance conferred by a
KRAS gene mutation following the administration of cetuximab: a case
report. BMC Research Notes 2013 6:508.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
